SG11202002088TA - Methods and compositions for treating chronic lung diseases - Google Patents

Methods and compositions for treating chronic lung diseases

Info

Publication number
SG11202002088TA
SG11202002088TA SG11202002088TA SG11202002088TA SG11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA SG 11202002088T A SG11202002088T A SG 11202002088TA
Authority
SG
Singapore
Prior art keywords
compositions
methods
treating chronic
lung diseases
chronic lung
Prior art date
Application number
SG11202002088TA
Inventor
Norman Barton
Alexandra Mangili
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of SG11202002088TA publication Critical patent/SG11202002088TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
SG11202002088TA 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases SG11202002088TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762557113P 2017-09-11 2017-09-11
PCT/US2018/050427 WO2019051474A1 (en) 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases

Publications (1)

Publication Number Publication Date
SG11202002088TA true SG11202002088TA (en) 2020-04-29

Family

ID=63794620

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002088TA SG11202002088TA (en) 2017-09-11 2018-09-11 Methods and compositions for treating chronic lung diseases

Country Status (19)

Country Link
US (2) US20190151411A1 (en)
EP (1) EP3681602A1 (en)
JP (2) JP2020533344A (en)
KR (1) KR20200097679A (en)
CN (1) CN111432881A (en)
AU (1) AU2018328827A1 (en)
BR (1) BR112020004760A2 (en)
CA (1) CA3075482A1 (en)
CL (1) CL2020000597A1 (en)
CO (1) CO2020004244A2 (en)
EA (1) EA202090705A1 (en)
EC (1) ECSP20055797A (en)
IL (1) IL273174A (en)
MX (1) MX2020002744A (en)
PE (1) PE20201166A1 (en)
PH (1) PH12020500489A1 (en)
SG (1) SG11202002088TA (en)
WO (1) WO2019051474A1 (en)
ZA (1) ZA202001568B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202233228A (en) * 2020-10-19 2022-09-01 美商舒爾人類基因療法公司 Compositions suitable for use in neonates
WO2023213908A1 (en) * 2022-05-04 2023-11-09 Oak Hill Bio Limited Combination therapy for preterm infants
WO2023242440A1 (en) * 2022-06-17 2023-12-21 Oak Hill Bio Limited Treament of lungs in infants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of mature human IGF and EGF via prokaryotic recombinant DNA technology
WO1988007863A1 (en) 1987-04-06 1988-10-20 Biogrowth, Inc. Human somatomedin carrier protein subunits and process for producing them
DK131988A (en) 1988-03-11 1989-09-12 Erasmus University IGF BINDING PROTEIN, DNA STRUCTURE CODING FOR IGF BINDING PROTEIN AND VECTOR CONTAINING THIS DNA STRUCTURE
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (en) 1988-04-12 1996-01-15 Amgen Boulder Inc METHOD FOR INCREASE AND INHIBITING THE EFFECT OF AN INSULIN-LIKE GROWTH FACTOR
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
JPH07508025A (en) 1992-05-08 1995-09-07 トーマス・ジェファーソン・ユニバーシティ Insulin-like growth factor (IGF-1) analogs
US5563046A (en) 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5789547A (en) 1995-06-07 1998-08-04 Celtrix Pharmaceuticals, Inc. Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
CA2429615C (en) * 2000-11-28 2016-07-12 Children's Medical Center Corporation Determination of risk and treatment of complications of prematurity
EP2148695B1 (en) * 2007-04-18 2014-10-15 Premacure AB Method and product for treatment and/or prevention of complications of prematurity

Also Published As

Publication number Publication date
US20190151411A1 (en) 2019-05-23
ZA202001568B (en) 2023-09-27
JP2020533344A (en) 2020-11-19
BR112020004760A2 (en) 2020-09-15
EP3681602A1 (en) 2020-07-22
KR20200097679A (en) 2020-08-19
CN111432881A (en) 2020-07-17
CA3075482A1 (en) 2019-03-14
EA202090705A1 (en) 2020-06-11
PE20201166A1 (en) 2020-10-28
CL2020000597A1 (en) 2020-12-04
ECSP20055797A (en) 2020-10-30
JP2023145646A (en) 2023-10-11
MX2020002744A (en) 2020-10-01
AU2018328827A1 (en) 2020-04-02
IL273174A (en) 2020-04-30
US20220088132A1 (en) 2022-03-24
CO2020004244A2 (en) 2020-05-29
WO2019051474A1 (en) 2019-03-14
PH12020500489A1 (en) 2021-02-22

Similar Documents

Publication Publication Date Title
IL304820A (en) Compositions and methods for treating cancer
SG11201705093UA (en) Composition for treating il-6-related diseases
EP3319976A4 (en) Compositions and methods for treating lung diseases and lung injury
PT3377516T (en) Methods and compositions for treating cancer
HK1254432A1 (en) Methods and compositions for treating fibrotic diseases
EP3612215A4 (en) Compositions and methods for treating lung inflammation
IL290150A (en) Compositions and methods for the treatment of chronic pain
EP3139928A4 (en) Anordrin compositions and methods for treating diseases
SG10201913400QA (en) Methods for treating lung disorders
IL269158A (en) Compositions and methods for treating inflammatory diseases
IL256523A (en) Compositions and methods for treating cancer
EP3110446A4 (en) Methods and compositions for treating siglec-8 associated diseases
IL255079A0 (en) Methods for treating lung cancer
ZA201605492B (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
IL261010B (en) Compositions and methods for treating chronic wounds
EP3322406A4 (en) Transpapillary methods and compositions for treating breast disorders
IL259710A (en) Compositions and methods of treatment for mvid and related diseases
SG11202002088TA (en) Methods and compositions for treating chronic lung diseases
IL255638A (en) Compositions and methods for treating cancer
HK1244782A1 (en) Compositions and methods for treating diseases and conditions
IL272945A (en) Topical compositions and methods for treatment
HK1251490A1 (en) Compositions and methods for immune-mediated cancer therapy
HK1250958A1 (en) Compositions and methods for treating cancer
EP3463422A4 (en) Compositions and methods for treating metabolic diseases
EP3273965A4 (en) Composition and methods for treating chronic kidney disease